# US 2025/0157586 A1 · Methods and systems for determining her2 status using molecular data

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0157586 A1
- Document ID: US20250157586A1
- Status: Published application
- Kind: A1
- Application number: 18/949,713
- Filed: 2024-11-15
- Published: 2025-05-15
- Earliest claimed: 2023-11-15
- Assignees: Tempus AI, Inc.
- Applicants: Tempus Ai, Inc.
- Inventors: Talal Ahmed; Raphael Pelossof; Mark Carty; Kaveri Nadhamuni
- Web page: https://patentgrep.com/patent/US20250157586A1

## CPC

- G16B 40/20: Supervised data analysis
- A61B 10/0041: {Detection of breast cancer (mammography by transillumination A61B5/0091, by X-rays A61B6/502, by ultrasonic means A61B8/0825)}
- G16B 20/00: ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
- G16H 10/40: for data related to laboratory analysis, e.g. patient specimen analysis
- G16H 20/10: relating to drugs or medications, e.g. for ensuring correct administration to patients
- G16H 50/20: for computer-aided diagnosis, e.g. based on medical expert systems
- G16H 15/00: ICT specially adapted for medical reports, e.g. generation or transmission thereof
- G16B: BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- A61B: DIAGNOSIS; SURGERY; IDENTIFICATION (usefulness limited to only animals A61D)
- G16H: HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA

## Abstract

A computer-implemented method, computing system and computer-readable medium for determining HER2-low status of a patient using molecular data of the patient includes: (a) receiving digital biological data; (b) processing the digital biological data using a trained multi-stage machine learning architecture; (c) generating a digital HER2-low status report corresponding to the patient; and (d) causing the digital HER2-low status report to be displayed. A computer-implemented method, computing system and computer-readable medium for training a model architecture to determine HER2-low status of a patient using molecular data of the patient includes: (a) receiving training digital biological data; (b) initializing a machine learning model; (c) processing the plurality of molecular signatures using the machine learning model to generate a trained machine learning model; and (d) storing the trained machine learning.

## Claims

### Claim 1

A computer-implemented method for determining HER2-low status of a patient using molecular data of the patient, comprising:
receiving, via one or more processors, digital biological data;
processing, via one or more processors, the digital biological data corresponding to the patient using a trained multi-stage machine learning architecture, wherein the processing includes:
(i) processing the digital biological data using a trained HER2-positive model to determine whether the digital biological data indicates that a HER2 status of the patient is HER2-positive;
(ii) when the HER2 status of the patient is not HER2-positive, processing the digital biological data using a trained HER2-low model to identify whether the HER2 status of the patient is HER2-low; and
(iii) when the HER2 status of the patient is not HER2-positive or HER2-low, designating the HER2 status of the patient as HER2-negative;
generating, via one or more processors, a digital HER2-low status report corresponding to the patient; and
causing, via a display device, the digital HER2-low status report to be displayed.

### Claim 2 (depends on 1)

The computer-implemented method of claim 1, wherein the digital biological data includes RNA data.

### Claim 3 (depends on 1)

The computer-implemented method of claim 1, wherein the digital biological data includes at least some transcriptomic data.

### Claim 4 (depends on 3)

The computer-implemented method of claim 3, wherein the at least some of the transcriptomic data includes at least some data generated via RNA seq.

### Claim 5 (depends on 1)

The computer-implemented method of claim 1, wherein the digital biological data includes at least one of DNA data or copy number variant data.

### Claim 6 (depends on 1)

The computer-implemented method of claim 1, wherein receiving the digital biological data includes receiving the digital biological data from a next-generation sequencing platform.

### Claim 7 (depends on 1)

The computer-implemented method of claim 1, wherein the trained HER2-positive model is a random forest model.

### Claim 8 (depends on 1)

The computer-implemented method of claim 1, wherein the trained HER2-low model is a random forest model.

### Claim 9 (depends on 1)

The computer-implemented method of claim 1, wherein the trained HER2-positive model is a binary classifier trained on molecular signature data labeled according to (HER2-positive, NOT-HER2-positive) labels.

### Claim 10 (depends on 1)

The computer-implemented method of claim 1, wherein the trained HER2-low model is a binary classifier trained on molecular signature data labeled according to (HER2-low, NOT-HER2-low) labels.

### Claim 11 (depends on 1)

The computer-implemented method of claim 1, further comprising:
generating a prediction as to the HER2-low, HER2-positive and/or HER2-negative status of a given sample based on the trained multi-stage machine learning architecture.

### Claim 12 (depends on 1)

The computer-implemented method of claim 1, further comprising:
identifying at least one patient from a population of patients by processing the data of the patient using trained multi-stage machine learning architecture; and
matching the identified patient for treatment using a targeted therapy.

### Claim 13 (depends on 12)

The computer-implemented method of claim 12, wherein the targeted therapy is a HER2 targeted therapy.

### Claim 14 (depends on 13)

The computer-implemented method of claim 13, wherein the targeted therapy is trastuzumab deruxtecan.

### Claim 15

A computing system comprising:
one or more processors; and
one or more memories having stored thereon computer-readable instructions that, when executed, cause the computing system to:
receive digital biological data;
process the digital biological data corresponding to a patient using a trained multi-stage machine learning architecture, wherein the processing includes:
(i) processing the digital data using a trained HER2-positive model to determine whether the digital biological data indicates that a HER2 status of the patient is HER2-positive;
(ii) when the patient is not HER2-positive, processing the digital biological data using a trained HER2-low model to identify whether the HER2 status of the patient is HER2-low; and
(iii) when the patient is not HER2-positive or HER2-low, designating the HER2 status of the patient as HER2-negative;
generate, via one or more processors, a digital HER2-low status report corresponding to the patient; and
causing, via a display device, the digital HER2-low status report to be displayed.

### Claim 16 (depends on 15)

The computing system of claim 15, wherein the digital biological data includes one or both of (i) RNA data, and (ii) at least some transcriptomic data.

### Claim 17 (depends on 15)

The computing system of claim 15, wherein the at least some of the transcriptomic data includes at least some data generated via RNA seq.

### Claim 18

A computer-readable medium having stored thereon computer-executable instructions that, when executed, cause a computer to:
receive digital biological data;
process the digital biological data corresponding to a patient using a trained multi-stage machine learning architecture, wherein the processing includes:
(i) processing the digital data using a trained HER2-positive model to determine whether the digital biological data indicates that a HER2 status of the patient is HER2-positive;
(ii) when the patient is not HER2-positive, processing the digital biological data using a trained HER2-low model to identify whether a HER2 status of the patient is HER2-low; and
(ii) when the patient is not HER2-positive or HER2-low, designating the HER2 status of the patient as HER2-negative;
generate, via one or more processors, a digital HER2-low status report corresponding to the patient; and
cause, via a display device, the digital HER2-low status report to be displayed.

### Claim 19 (depends on 18)

The computer-readable medium of claim 18, wherein the digital biological data includes one or both of (i) RNA data, and (ii) at least some transcriptomic data.

### Claim 20 (depends on 18)

The computer-readable medium of claim 18, wherein the at least some of the transcriptomic data includes at least some data generated via RNA seq.
